Invention Grant
- Patent Title: PD-L1 based immunotherapy
-
Application No.: US14352407Application Date: 2012-10-17
-
Publication No.: US09669078B2Publication Date: 2017-06-06
- Inventor: Mads Hald Andersen
- Applicant: Herlev Hospital
- Applicant Address: DK Herlev
- Assignee: Herlev Hospital
- Current Assignee: Herlev Hospital
- Current Assignee Address: DK Herlev
- Agency: Dinsmore & Shohl LLP
- Priority: DK201170574 20111017
- International Application: PCT/DK2012/050386 WO 20121017
- International Announcement: WO2013/056716 WO 20130425
- Main IPC: A61K38/04
- IPC: A61K38/04 ; A61K38/17 ; C07K9/00 ; C07K14/00 ; A61K39/00
Abstract:
The present invention relates to the field of prophylaxis and therapy of clinical conditions including cancer, autoimmune diseases and infectious diseases. In particular there is provided vaccine compositions comprising PD-L1 or peptide fragments thereof that are capable of eliciting immune responses useful in treatment of cancer, autoimmune diseases or infectious diseases.
Public/Granted literature
- US20140242101A1 PD-L1 BASED IMMUNOTHERAPY Public/Granted day:2014-08-28
Information query
IPC分类:
